SFDA To More Closely Monitor Avandia Drug Safety
This article was originally published in PharmAsia News
Executive Summary
In light of new cardiovascular safety concerns for patients taking Avandia (rosiglitazone), China's State FDA will focus more drug safety monitoring efforts on the drug